Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management

• by Guillermo Garcia-Manero

• July 3, 2026

The evolution of RTOG and NRG Oncology CNS tumors clinical trials

• by Kavita Sehrawat, Mei-Yin C. Polley, Michael A. Vogelbaum, Mark Gilbert, Arnab Chakravarti, Daniel P. Cahill, Andrew B. Lassman, David R. Raleigh, Erik P. Sulman, Mitch Machtay, Quynh Thu Le, Walter Curran, Vinai Gondi, Minesh P. Mehta

• September 15, 2026

Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors

• by Renato Cuocolo, Andrea Ponsiglione, Georgios Agrotis, Tristan Barrett, Giorgio Brembilla, Iztok Caglic, Hanna Falińska, Charlie Alexander Hamm, Emanuele Messina, Tobias Penzkofer, Raphaële Renard-Penna, Olivier Rouvière, Luca Russo, Evis Sala, Johannes Uhlig, Anwar R. Padhani, Maarten de Rooij

• September 18, 2026

Musings from The Power List: Dajun Yang

The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics

• September 15, 2026

• 5 min